{"id":46168,"date":"2023-09-28T13:00:00","date_gmt":"2023-09-28T13:00:00","guid":{"rendered":"https:\/\/ogkologos.com\/2023-asco-annual-meeting-research-round-up-new-research-in-treating-lung-cancer-and-mesothelioma\/"},"modified":"2024-11-03T15:12:22","modified_gmt":"2024-11-03T15:12:22","slug":"2023-asco-annual-meeting-research-round-up-new-research-in-treating-lung-cancer-and-mesothelioma","status":"publish","type":"post","link":"https:\/\/ogkologos.com\/en\/2023-asco-annual-meeting-research-round-up-new-research-in-treating-lung-cancer-and-mesothelioma\/","title":{"rendered":"2023 ASCO Annual Meeting Research Round Up: New Research in Treating Lung Cancer and Mesothelioma"},"content":{"rendered":"<p>In the annual Research Round Up series, Cancer.Net Editorial Board members answer the question, \u201cWhat was the most exciting or practice-changing research in your field presented at the 2023 ASCO Annual Meeting?\u201d In this episode, 3 Cancer.Net Editorial Board members discuss new research presented at the meeting in treating <a href=\"https:\/\/www.cancer.net\/cancer-t%C3%BDpes\/lung-cancer-non-small-cell\">non-small cell lung cancer<\/a> (NSCLC), <a href=\"https:\/\/www.cancer.net\/cancer-types\/lung-cancer-small-cell\/\">small cell lung cancer<\/a> (SCLC), and <a href=\"https:\/\/www.cancer.net\/cancer-types\/mesothelioma\">mesothelioma<\/a>.<\/p>\n<p>Listen below, and&nbsp;<a href=\"https:\/\/www.cancer.net\/blog\/podcasts\">subscribe to Cancer.Net Podcasts<\/a>&nbsp;wherever you listen to podcasts for new episodes in this series.<\/p>\n<h3>Advancing treatment for lung cancer and mesothelioma<\/h3>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/www.cancer.net\/sites\/cancer.net\/files\/aggarwal-marmarelis-higgins.png\" width=\"225\" height=\"113\">Dr. Charu Aggarwal, the 2023 <a href=\"https:\/\/www.cancer.net\/about-us\/cancernet-editorial-board\/associate-editors\/charu-aggarwal-md-mph\">Cancer.Net Associate Editor for Lung Cancer<\/a>, leads a robust discussion with Dr. Melina Marmarelis, the 2023 <a href=\"https:\/\/www.cancer.net\/about-us\/cancernet-editorial-board\/specialty-editors\/melina-marmarelis-md-msce\">Cancer.Net Specialty Editor for Mesothelioma<\/a>, and Dr. Kristin A. Higgins, a 2023 <a href=\"https:\/\/www.cancer.net\/about-us\/cancernet-editorial-board\/advisory-panel\">Cancer.Net Lung Cancer Advisory Panelist<\/a>, on advancements in treating lung cancer and mesothelioma. Together, they cover 6 studies, including:<\/p>\n<ul readability=\"12.575535168196\">\n<li readability=\"1.7028112449799\">\n<p>The phase 3 <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02511106\" target=\"_blank\" rel=\"noopener\">ADAURA clinical trial<\/a>, which studied whether giving the <a href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/personalized-and-targeted-therapies\/what-targeted-therapy\">targeted therapy<\/a> drug osimertinib (Tagrisso) after surgery could help people with stage IB to IIIA NSCLC with an <i>epidermal growth factor receptor (EGFR)<\/i> mutation live longer. [4:00]<\/p>\n<\/li>\n<li readability=\"3.4243542435424\">\n<p>The phase 3 <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03425643\" target=\"_blank\" rel=\"noopener\">KEYNOTE-671 clinical trial<\/a>, which evaluated whether using the <a href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/immunotherapy-and-vaccines\/what-immunotherapy\">immunotherapy<\/a> drug pembrolizumab (Keytruda) both before and after surgery could reduce the chances of the cancer coming back and help people with stage IIA, IIIA, and IIIB NSCLC live longer. [9:33]<\/p>\n<\/li>\n<li readability=\"0.81914893617021\">\n<p>The phase 3 <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02784171\" target=\"_blank\" rel=\"noopener\">IND227 clinical trial,<\/a> which looked at whether adding pembrolizumab to <a href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/chemotherapy\">chemotherapy<\/a> could help people with pleural mesothelioma who did not receive surgery live longer. [14:55]<\/p>\n<\/li>\n<li readability=\"1.7805907172996\">\n<p>The phase 3 <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03515837\" target=\"_blank\" rel=\"noopener\">KEYNOTE-789 clinical trial<\/a>, which examined whether adding pembrolizumab to chemotherapy affected outcomes for people with NSCLC with an <i>EGFR<\/i> mutation whose cancer had grown following treatment with a targeted therapy. [17:28]<\/p>\n<\/li>\n<li readability=\"2.5225225225225\">\n<p>The phase 2 <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04334941\" target=\"_blank\" rel=\"noopener\">SWOG S1929 clinical trial<\/a>, which studied whether <a href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/how-cancer-treated\/what-maintenance-therapy\">maintenance therapy<\/a> with the immunotherapy drug atezolizumab (Tecentriq) in combination with the targeted therapy drug talazoparib (Talzenna) could delay cancer growth in people with extensive stage SCLC that tested positive for the <a href=\"https:\/\/www.cancer.net\/navigating-cancer-care\/diagnosing-cancer\/tests-and-procedures\/tumor-marker-tests\">biomarker<\/a> Schlafen-11 (SLFN11). [20:30]<\/p>\n<\/li>\n<li readability=\"4.6022727272727\">\n<p>The <a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT02973789\" target=\"_blank\" rel=\"noopener\">phase 3 LUNAR clinical trial<\/a>, which assessed whether adding tumor treating field therapy to standard treatment could help people with metastatic NSCLC live longer. During tumor treating field therapy, a noninvasive, wearable device is placed on the skin that produces an electrical field to help stop tumor cells from growing and spreading. [24:33]<\/p>\n<\/li>\n<\/ul>\n<p>Disclosure information for this podcast\u2019s speakers can be found in their individual biographies linked to above.<\/p>\n<p><b><i>Was this podcast useful?<\/i><\/b> <i>Please subscribe, rate, and review Cancer.Net Podcasts wherever you listen to podcasts. This prerecorded podcast can be listened to online or downloaded to your computer. A <a href=\"https:\/\/www.cancer.net\/blog\/podcasts\/2023-research-round-lung-cancer\">transcript<\/a> is also available. For more information, visit the <\/i><a href=\"http:\/\/www.cancer.net\/blog\/podcasts\"><i>Cancer.Net podcast page<\/i><\/a><i><span>.<\/span><\/i><\/p>\n<p><i>Cancer.Net podcasts are edited for length and content. <\/i><\/p>\n<p><a href=\"https:\/\/www.cancer.net\/blog\/2023-09\/2023-asco-annual-meeting-research-round-new-research-treating-lung-cancer-and-mesothelioma\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>In the annual Research Round Up series, Cancer.Net Editorial Board members answer the question, \u201cWhat was the most exciting or practice-changing research in your field presented at the 2023 ASCO Annual Meeting?\u201d In this episode, 3 Cancer.Net Editorial Board members discuss new research presented at the meeting in treating non-small cell lung cancer (NSCLC), small [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[5137],"tags":[],"class_list":["post-46168","post","type-post","status-publish","format-standard","hentry","category-world-news"],"_links":{"self":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46168","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/comments?post=46168"}],"version-history":[{"count":1,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46168\/revisions"}],"predecessor-version":[{"id":46250,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/posts\/46168\/revisions\/46250"}],"wp:attachment":[{"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/media?parent=46168"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/categories?post=46168"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ogkologos.com\/en\/wp-json\/wp\/v2\/tags?post=46168"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}